Why the study?
How should direct oral anticoagulants be implemented in clinical practice for patients with atrial fibrillation and venous thromboembolism?
How should direct oral anticoagulants be implemented in clinical practice for patients with atrial fibrillation and venous thromboembolism?
Answers are grounded in this paper and cite their sources.
This article provides practical guidance on selecting and implementing direct oral anticoagulants, which are safe and effective alternatives to vitamin K antagonists, in clinical practice.
Vitamin K antagonists, such as warfarin, have been the anticoagulants of choice for many years for patients with AF and other thrombotic conditions. The introduction of direct oral anticoagulants (DOACs) as alternatives represents a major advance in anticoagulation. DOACs have been found to be at least as safe and effective as vitamin K antagonists in randomised, controlled trials for stroke prevention in AF and the management of venous thromboembolism, with real-world data showing similar outcomes. With the availability of several agents, selecting the most appropriate DOAC can be challenging. The aim of the present article is to provide useful guidance on the implementation of DOAC treatment in clinical practice.
No takes yet. Share an insight, caveat, or question.
Julia et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: